# Bridford Investments

> Bridford Investments is a VC fund backing Biotechnology, Manufacturing and Energy. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 6
- Last investment: Dec 2022
- Lead investor: 33%
- Last updated: Aug 2026

Bridford Investments is a VC fund focused on Biotechnology and Manufacturing. Bridford Investments

## Round sizes

| Stage | Round size |
| --- | --- |
| Venture - Series Unknown | $23M–$2.8B |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 33% |
| Manufacturing | 2 | 33% |
| Energy | 1 | 17% |
| Battery | 1 | 17% |
| Cycling | 1 | 17% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Venture - Series Unknown | 3 | 50% |
| Series A | 1 | 17% |
| Series B | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Sweden | 1 | 17% |
| Belgium | 1 | 17% |
| Finland | 1 | 17% |
| United Kingdom | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Classified Cycling | A manufacturing company engaged in the development and commercialization of cycling drivetrain products, Classified Cycling develops and manufactures products for the cycling industry. The company utilizes its Powershift technology that improves on the conventional front derailleur and offers electronic shifting, which enables instantaneousshifting under full loads and with uncompromised gear ratios. | $23.2M | Venture - Series Unknown | Dec 01, 2022 |  |
| Touchlight Genetics | Founded in 2008, Touchlight brings together a highly talented scientific and drug development team supported by an experienced board.Founder and CEO Jonny Ohlson has assembled a dynamic management team, including Clive Dix, Non Executive Chairman, and John Tite, Executive Head of Research (formerly founding CEO of Bicycle Therapeutics), withsubstantial experience in growing life science companies and particularly in DNA vaccines. Touchlight is supported by a group of Non-Executive Directors, who bring a wealth of healthcare and entrepreneurial experience.Led by experienced drug pharmaceutical scientists Neil Porter and Jill Makin, Touchlight’s scientific team- some of the brightest talents in the UK industry- has successfully established and patented the proTLx™ synthetic DNA platform as well as successfully establishing the first therapeutic proof-of-principle through collaboration with leading academic partners.The company has established strong collaborative links with academic laboratories worldwide including Imperial College London, Southampton University, Queen’s University Belfast and the University of Pennsylvania in the US. | $69.2M | Venture - Series Unknown | Sep 15, 2021 |  |
| Northvolt | Northvolt develops sustainable lithium-ion batteries in conjunction with R&D, industrialization, and recycling to support clean energy. It provides electrification and renewable energy storage designed for lithium-ion battery plant to produce batteries for electric vehicles. Northvolt's product is an environment-friendly batterymanufactured with minimal carbon footprint and with recycling technology without compromising with important eco-systems, enabling the auto industry to replace fossil fuels with electricity in an efficient manner. The company aims to establish a supply of sustainable battery cells and systems.In 2016, Paolo Cerruti and Peter Carlsson headquartered the company in Stockholm, Stockholms Lan. | $2.8B | Venture - Series Unknown | Jun 09, 2021 |  |
| Touchlight Genetics | Founded in 2008, Touchlight brings together a highly talented scientific and drug development team supported by an experienced board.Founder and CEO Jonny Ohlson has assembled a dynamic management team, including Clive Dix, Non Executive Chairman, and John Tite, Executive Head of Research (formerly founding CEO of Bicycle Therapeutics), withsubstantial experience in growing life science companies and particularly in DNA vaccines. Touchlight is supported by a group of Non-Executive Directors, who bring a wealth of healthcare and entrepreneurial experience.Led by experienced drug pharmaceutical scientists Neil Porter and Jill Makin, Touchlight’s scientific team- some of the brightest talents in the UK industry- has successfully established and patented the proTLx™ synthetic DNA platform as well as successfully establishing the first therapeutic proof-of-principle through collaboration with leading academic partners.The company has established strong collaborative links with academic laboratories worldwide including Imperial College London, Southampton University, Queen’s University Belfast and the University of Pennsylvania in the US. | $58.7M | Venture - Series Unknown | Mar 11, 2021 |  |
| Northvolt | Northvolt develops sustainable lithium-ion batteries in conjunction with R&D, industrialization, and recycling to support clean energy. It provides electrification and renewable energy storage designed for lithium-ion battery plant to produce batteries for electric vehicles. Northvolt's product is an environment-friendly batterymanufactured with minimal carbon footprint and with recycling technology without compromising with important eco-systems, enabling the auto industry to replace fossil fuels with electricity in an efficient manner. The company aims to establish a supply of sustainable battery cells and systems.In 2016, Paolo Cerruti and Peter Carlsson headquartered the company in Stockholm, Stockholms Lan. | $600M | Series B | Sep 29, 2020 |  |
| Solar Foods | Solar Foods is a food-tech startup that specializes in testing a technology that uses electricity to produce hydrogen which is combined with carbon dioxide, water, vitamins, and minerals to feed and grow microbial biomass that can be used as edible protein. The industrial biotech startup develops a protein called Solein, a nutritious, sustainablesubstitute for animal-derived proteins. Solein is created using elements from the air—CO2, water, nitrogen—and electricity. This single-cell protein is cultivated through gas fermentation, essentially deriving edible calories from hydrogen-oxidizing microbes. | $22.1M | Series A | Sep 01, 2020 |  |

6 of 6 investments shown.

## Co-investors
- [Baillie Gifford](https://shizune.co/investors/profile/baillie-gifford) — VC Fund, 2 deals together
- [Baron Capital](https://shizune.co/investors/profile/baron-capital) — VC Fund, 2 deals together
- [IMAS Foundation](https://shizune.co/investors/profile/imas-foundation) — VC Fund, 2 deals together
- [Norrsken VC](https://shizune.co/investors/profile/norrsken-vc) — VC Fund, 2 deals together
- [PCS Holding AG](https://shizune.co/investors/profile/pcs-holding-ag) — VC Fund, 2 deals together
- [Volkswagen Group](https://shizune.co/investors/profile/volkswagen-group) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund

### Similar country
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund
- [Lifeline Ventures](https://shizune.co/investors/profile/lifeline-ventures) — VC Fund
- [Tesi](https://shizune.co/investors/profile/tesi) — VC Fund

## Featured in investor lists
- [Food and Beverage VC Funds in Finland](https://shizune.co/investors/food-and-beverage-vc-funds-finland)
- [Biotechnology VC Funds in Finland](https://shizune.co/investors/biotechnology-vc-funds-finland)
- [Biotech VC Funds in Finland](https://shizune.co/investors/biotech-vc-funds-finland)
- [Food and Beverage Investors in Finland](https://shizune.co/investors/food-and-beverage-investors-finland)
- [Biotechnology Investors in Finland](https://shizune.co/investors/biotechnology-investors-finland)

## FAQ

### What does Bridford Investments invest in?

Bridford Investments invests primarily in Biotechnology, Manufacturing and Energy startups, most often at Venture - Series Unknown and Series A stage. Most of the 6 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Bridford Investments's check size?

Bridford Investments typically joins rounds of $23M–$2.8B at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Bridford Investments participates in.

### When did Bridford Investments last invest?

The most recent investment recorded for Bridford Investments closed in Dec 2022. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co